This story requires our BI Prime membership. To read the full article,Samantha Lee/Business Insider
The Cambridge-based company only raised its Series A last year and is looking to expand rapidly with its rare disease treatment programmes in a market worth an estimated $220 billion. It's part of a major push into new forms of biological engineering and tech-led health solutions in what's estimated to be a $220 billion market by Healx. Atomico principal Irina Haivas, a Healx board member, said that the company's combination of strong tech and drug expertise was a winning model in what she claims is a large and growing part of the market.
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: BusinessInsider - 🏆 729. / 51 Прочитайте больше »
Источник: BusinessInsider - 🏆 729. / 51 Прочитайте больше »
Источник: BusinessInsider - 🏆 729. / 51 Прочитайте больше »